Level Biotechnology

Level Biotechnology Book Value per Share

The Book Value per Share of Level Biotechnology (3118.TWO) as of Nov 5, 2026 is 17.88 TWD. In the previous year, Book Value per Share was 17.25 TWD — a change of 3.62% (higher).

Book Value per Share

17.88TWD

YoY

3.62%

Last updated:

Book Value per Share of Level Biotechnology is 2025 17.88 TWD. Book Value per Share of Level Biotechnology was 2024 17.25 TWD. It decreases by 3.62% higher compared to the previous year.

The Level Biotechnology Book Value per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Book Value per Share
Date
Book Value per Share
Jan 1, 2018
15.37 TWD
Jan 1, 2019
15.83 TWD
Jan 1, 2020
16.32 TWD
Jan 1, 2021
16.79 TWD
Jan 1, 2022
16.71 TWD
Jan 1, 2023
16.93 TWD
Jan 1, 2024
17.25 TWD
Jan 1, 2025
17.88 TWD
The Level Biotechnology Book Value per Share history
YEARBook Value per ShareYoY
17.88TWD+3.62%
17.25TWD+1.90%
16.93TWD+1.30%
16.71TWD-0.45%
16.79TWD+2.91%
16.32TWD+3.05%
15.83TWD+3.00%
15.37TWD-4.50%
16.09TWD+1.32%
15.88TWD-1.75%
16.17TWD+2.89%
15.71TWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Level Biotechnology Stock analysis

What does Level Biotechnology do? Level Biotechnology, Inc. generates revenue through the sale of biotechnological services and products. The company offers cell culture series, immune protein series, gene nucleic acid and molecular biology series, and instrument series to customers in the domestic market. Preclinical testing services, including genetic toxicity testing, general toxicology testing, reproductive toxicology testing, pharmacokinetic testing, and biocompatibility testing, are also provided as key revenue streams. Domestic market buyers primarily include research institutions and pharmaceutical companies seeking advanced biotech solutions. The firm's product portfolio targets the biotechnology and pharmaceutical sectors, with a focus on domestic customers. Cell culture series and molecular biology series are essential for laboratory research, while immune protein series supports immunological studies. Preclinical testing services cater to pharmaceutical firms requiring regulatory compliance for drug development. All products and services are distributed exclusively within the domestic market, ensuring focused market penetration and customer relationships. Level Biotechnology's revenue model relies on consistent demand for biotech products and testing services from domestic clients. The company's domestic market distribution strategy allows for tailored service delivery and strong client retention. By specializing in cell culture, molecular biology, and preclinical testing, Level Biotechnology maintains a competitive edge in the local biotech industry. Level Biotechnology is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Level Biotechnology stock

Book Value per Share of Level Biotechnology is 17.88 TWD in 2025.

Book Value per Share of Level Biotechnology changed from 17.25 TWD to 17.88 TWD, representing a 3.62% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Book Value per Share Level Biotechnology since 2006 – with annual values, charts, and detailed analysis.

Book value per share represents the net asset value of the company per outstanding share. Comparing it to the stock price helps assess whether a stock is undervalued.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Level Biotechnology

All Key Metrics — Level Biotechnology